Zheng Quan Zhi Xing·2025-07-16 11:19Core Viewpoint - The article discusses the qualification review conducted by Guotai Junan Securities Co., Ltd. regarding the share transfer of Shanghai Yizhong Pharmaceutical Co., Ltd. from its shareholder Shanghai Kaibao Pharmaceutical Co., Ltd. to specific institutional investors [1][2]. Group 1: Share Transfer Process - Guotai Junan was entrusted by Shanghai Kaibao to organize the inquiry transfer of shares before the initial public offering of Shanghai Yizhong [1]. - The inquiry transfer is conducted in accordance with relevant regulations, including the implementation opinions for the establishment of the Sci-Tech Innovation Board and the trial registration system [1]. Group 2: Qualification Review - Guotai Junan completed the qualification review of the transferor, which included interviews and inquiries, as well as the collection of relevant documents [1][2]. - The review confirmed that Shanghai Kaibao is a legally existing joint-stock company without any circumstances that would lead to its termination under national laws and regulations [2][3]. Group 3: Compliance with Regulations - The review found that Shanghai Kaibao does not fall under any prohibited circumstances outlined in the inquiry transfer and allocation guidelines, such as violations of share reduction regulations or other commitments [3][4]. - The transferor's shares are confirmed to be pre-IPO shares without any restrictions such as pledges or judicial freezes [4].